Articles tagged with Sickle Cell Anemia
Researchers at UH College of Pharmacy are developing breakthroughs to combat sepsis, a leading cause of hospital deaths, and diseases such as Alzheimer's and sickle cell disease. A dual-action nanomedicine has shown a 100% survival rate in preclinical trials for sepsis treatment.
Dr. Enrico Novelli leads a newly launched network to expand access to care for patients with sickle cell disease across Maryland. He brings expertise in SCD and blood vessel biology, as well as global efforts to strengthen hematology care.
Researchers found that blood stem cells from young patients with sickle cell disease have features of aging, which can increase the risk for other complications. Using senolytics improved disease symptoms in model systems, highlighting a needed improvement to gene therapies.
A 10-year study published in NEJM found hydroxyurea treatment significantly reduces serious complications, hospitalizations, and death from sickle cell anemia. The study demonstrated improved growth and development in Ugandan children with the disease.
A new study by the American Society of Hematology finds that stem cell transplantation is the most cost-effective option for long-term care of sickle cell disease in adults. Gene therapy, while promising, comes with an astronomical cost and requires a significant price reduction to be competitive.
A new study reveals significant variation in sickle cell disease hospitalizations and costs across New York State, with regional differences in access to specialized care and treatment impacting outcomes. Long Island and New York City show high costs and complex cases, while Central New York has the longest average length of stay.
Dr. Stuart Orkin has been awarded the Breakthrough Prize in Life Sciences for discovering genetic mechanisms underlying hemoglobin production and developing a therapy using CRISPR/Cas9 technology. The therapy, Casgevy, treats patients with sickle-cell anemia and beta-thalassemia, debilitating blood disorders affecting millions worldwide.
Sickle cell disease affects an estimated 7.74 million people worldwide, with sub-Saharan Africa accounting for two-thirds of global cases. Individuals living in this region are less likely to use medications or go to the hospital for pain crises, relying more on homeopathic remedies and delaying medical care.
A gene-edited treatment has shown remarkable success against severe sickle cell disease, with 27 out of 28 patients achieving a functional cure and no painful crises. The therapy uses CRISPR/Cas12a technology to modify stem cells and increase levels of fetal hemoglobin.
Dr. Carolyn J. Anderson has been awarded a $100,000 grant from the SNMMI Mars Shot Research Fund to develop a PET radiotracer for imaging vaso-occlusive crisis in sickle cell disease. The award will support the production and validation of an easy-to-produce and high-yielding PET radiotracer, 18F-LLP2A, for rapid translation to patients.
A study by Yale School of Medicine found that 60% of physicians who treat sickle cell disease reported burnout, compared to 43% of those who do not. The data also showed that less job pride and less recreation time were associated with increased burnout.
Researchers discovered that highly 'stiff' red blood cells play a crucial role in sickle cell disease, causing blockages and pain. The study's findings could lead to more effective, personalized therapies and new testing for early warning of symptoms.
A new study found that young adults with complex childhood-onset conditions experience longer hospital stays, higher readmission rates, and greater use of resources in adult hospitals. These patients account for 6.7% of young adult hospitalizations but occupy 10.7% of all hospital bed-days.
The collaboration aims to deliver life-saving treatments at a fraction of their current market cost, using Caring Cross's decentralized manufacturing model. Clinical data demonstrated robust increases in fetal hemoglobin with sustained mitigation of SCD disease manifestations.
Researchers have demonstrated memantine's efficacy in stabilizing red blood cells and reducing hospitalizations for sickle cell patients. The treatment was found to be well-tolerated and showed a clear clinical benefit, particularly in children experiencing fewer painful flare-ups.
Preliminary results from trials of gene therapy exa-cel suggest the therapy offers an effective cure for beta-thalassemia and sickle cell disease in children younger than 12. The therapy's potential to prevent irreversible complications makes it potentially more beneficial in children than adults.
A study of over 1,000 patients found that hematopoietic cell transplantation eliminated sickle cell disease symptoms in most patients, with a 90% seven-year survival rate. Late effects were mostly liver and lung issues, but the procedure's benefits outweighed risks for many patients.
Researchers found that taking hydroxyurea during or shortly before pregnancy does not appear to cause specific issues in newborns, but recommend discontinuing the drug before conception due to potential risks. The study included data from 245 pregnancies involving hydroxyurea exposure and showed no maternal deaths or hydroxyurea-relate...
A study assessing the commercial roll-out of gene therapies for sickle cell disease and beta thalassemia reveals operational differences between two treatments. The median time to complete treatment was around 9-10 months, with most patients requiring only one cell collection procedure.
A recent study found that only one-third of patients with sickle cell disease received guideline-adherent pain treatment within the first hour at emergency departments. The study analyzed data from over 398,000 visits and found disparities in treatment based on age, sex, and insurance status.
A new study by Carnegie Mellon University's Wood Neuro Research Group uses advanced brain imaging and a digital visualization tool to better understand how pain is processed in the brain for people with sickle cell disease. The team found that patients had reduced connectivity across key brain networks linked to pain perception, partic...
Researchers developed a real-time QPM processing algorithm on an embedded GPU system, enabling rapid blood profiling for point-of-care diagnostics. The system can analyze over 100,000 cells in under 3 minutes and reported highly accurate results with an average error of less than 5 percent.
A biomarker study found that low placental growth factor (PlGF) levels can predict early-onset preeclampsia in pregnant women with sickle cell disease. The researchers identified a PlGF threshold of 87 pg/mL at 20-24 weeks as effective for predicting early-onset preeclampsia and late-onset preeclampsia, respectively.
A study published in Blood Advances found that individuals with sickle cell disease who were triaged appropriately received their first dose of pain medication within 60 minutes, while those triaged at lesser severity levels waited nearly three times as long. The researchers analyzed the impact of emergency severity index (ESI) assignm...
Researchers at UT Dallas discovered a connection between chronic sickle cell disease pain and the bacteria present in the gastrointestinal tract. By transplanting beneficial bacteria into mice with sickle cell disease, they alleviated chronic pain, highlighting the role of gut microbiomes in driving chronic pain.
A new study found that fewer than half of children with sickle cell disease and Medicaid in Michigan received dental services. Dental health is crucial for these children due to the reciprocal relationship between the disease and oral infections.
Treatment with exagamglogene autotemcel (exa-cel) leads to clinically meaningful improvements in overall quality of life for patients with severe sickle cell disease and transfusion-dependent beta thalassemia. Patients experience substantial improvements in physical, social, functional, and emotional well-being, with sustained benefits...
Researchers have developed a new epigenetic editing method using CRISPR technology, which can switch genes back on by removing methyl groups attached to silenced or suppressed genes. This approach shows promise for treating people with Sickle Cell-related diseases, reducing the risk of unwanted changes and potential health problems.
Dr. Machado brings scientific expertise, clinical leadership, and mentorship to the Department of Medicine at UMSOM. He will advance research impact, enhance clinical excellence, and shape the future of academic medicine.
A new study by Mass General Brigham investigators identified an ancient immune pathway that is activated in patients with acute chest syndrome (ACS) and serves as a key driver of the disease. Blocking this pathway with clinically approved drugs alleviated disease severity in preclinical models.
Gene therapy has been shown to significantly improve blood flow in the brains of patients with sickle cell disease, decreasing the risk of stroke. The treatment has a more substantial and long-lasting protective effect than other treatments like hydroxyurea or blood transfusions.
Researchers have found a promising new method for gene therapy by bringing dormant genes closer to enhancer switches on the DNA. This 'delete-to-recruit' strategy has potential for treating genetic diseases such as sickle cell disease and beta-thalassemia, offering an alternative to expensive current treatments.
A new algorithm standardizes care for children with sickle cell disease who present to the ED with a fever, reducing hospitalizations by 10% without increasing readmissions. The algorithm uses predefined risk factors to determine treatment, making it safer and more efficient.
Researchers at MD Anderson Cancer Center have made significant discoveries in three key areas of cancer care. In a study on sickle cell disease, the team found that the disorder can suppress immunity by altering DNA structure in CD8+ T cells, leading to potential strategies for improving immunotherapy responses. Meanwhile, a biomarker-...
A real-world study of 2,147 children with sickle cell disease found that hydroxyurea reduced emergency department visits by 0.36 fewer times per patient-year and hospital stays by 0.84 fewer days per patient-year. Improvements in hemoglobin concentration were seen only in patients who consistently took the medication.
Researchers have discovered a significant increase in inflammation and C-reactive protein levels in female patients with sickle cell disease during the follicular phase of their menstrual cycle. This finding may help identify potential targets for managing pain crises, particularly when combined with hormonal contraceptives.
Researchers created a thromboinflammation-on-a-chip model that can sustain blood clots for several months and track treatment options. This model reveals critical information on clot resolution and suggests new drug combinations to protect endothelial function in patients with sickle cell disease.
Researchers have identified a potential new gene target, FLT1, that could be edited to treat sickle cell disease by increasing fetal hemoglobin levels. The study found 14 new genetic markers associated with fetal hemoglobin production, which could help preserve the type of hemoglobin present at birth.
Dr. Sarah Du, an associate professor at Florida Atlantic University's College of Engineering and Computer Science, has been selected as a Senior Member of the National Academy of Inventors for her significant contributions to advancing medical technology. Her research focuses on developing point-of-care diagnostic tools and monitoring ...
A novel bone marrow transplant process has been shown to be safe and curative for adults with sickle cell disease, offering a viable alternative to recent gene therapy products. The treatment, which uses a 'half-matched' donor, results in high cure rates and low side effects, making it a more accessible option for patients.
A systematic literature review found no evidence to support a link between physical exertion without rhabdomyolysis or heat injury and sudden death in individuals with sickle cell trait. The review's findings refute the attribution of sudden death to SCT, a condition affecting over 100 million people worldwide.
A study found that individuals with sickle cell disease have brains that appear 14 years older than their actual age, and socioeconomic status is also linked to brain health in adults. This can lead to cognitive problems and challenges in school and work.
Researchers found significantly higher levels of p16INK4a in young people with sickle cell disease, indicating accelerated cellular aging. This discovery may lead to new treatments targeting cell aging and improved quality of life for SCD patients.
Researchers have identified a promising new drug, lomonitinib, targeting treatment-resistant acute myeloid leukemia (AML) with FLT-3 mutation. Additionally, they developed a novel compound to target MALT1 protein in chronic lymphocytic leukemia (CLL), aiming to provide better control of the disease.
Branden Baptiste, 20, becomes the world's first patient to receive base editing gene therapy for sickle cell disease. The treatment has left him feeling 'more than fine' with no symptoms of the disease. After undergoing chemotherapy and a series of tests, Branden was infused with genetically treated cells in December 2023, allowing his...
Researchers at UCSF are enrolling patients in a clinical trial to correct the genetic mutation causing sickle cell disease using non-viral CRISPR-Cas9 gene editing. The therapy aims to eliminate the need for a bone marrow transplant and create a new blood system free of the disease.
Researchers developed a novel lentivirus-based gene therapy strategy in CD34+ hematopoietic progenitor cells, which showed therapeutic levels of expression of the anti-sickling beta globin protein. Cyclosporin improved transduction efficiency and preserved cell viability.
Researchers at Indiana University are developing next-generation ophthalmoscopes to spot early warning signs of diseases like Alzheimer's, diabetes, and heart disease with a simple eye scan. The technology uses machine learning and AI to reduce diagnosis time from days to minutes.
A new study found that preschool-aged children with sickle cell disease who live in food deserts and have limited access to transportation are at greater risk for acute complications and hospitalizations. Living in a household located more than one mile from a supermarket was associated with a 44% increase in hospitalizations.
A study found that stroke rates are rising among adults with SCD, despite established treatment guidelines, with age being a significant factor. The researchers identified modifiable risk factors such as high blood pressure, high cholesterol, and frequent hospitalization as increasing the risk of ischemic stroke.
A study found that individuals with sickle cell trait have a 1.45-fold higher risk of venous thromboembolism, similar across all genetic ancestry groups. Carriers for Factor V Leiden had an even higher risk of blood clots compared to those with sickle cell trait.
Research analyzing 4.184 million genetic data from 23andMe participants found that those with sickle cell trait have a higher risk of venous thromboembolism and pulmonary embolism, yet relatively lower risk of blood clotting overall compared to FVL.
Researchers found that low-intensity blood stem cell transplants did not damage lungs and may help improve lung function in adults with sickle cell disease. Overall lung function remained stable or improved in patients after the procedure, according to a three-year study.
Researchers discovered a new small molecule, SR-18292, that increases fetal hemoglobin production and reduces sickled red blood cells in mice with sickle cell disease. The study suggests that combining SR-18292 with hydroxyurea could provide a vital new treatment option for patients who don't respond well to traditional treatments.
A study suggests that hydroxyurea alters the developmental process of ovarian follicles but not their quantity. Ovarian tissue samples from patients with SCD showed no significant difference in primordial follicle density between those who received hydroxyurea and those who did not.
A study by Texas A&M University researchers found that individuals with sickle cell disease who experience a delay of more than six months after transferring from pediatric to adult care are twice as likely to be hospitalized compared to those who transition in less than two months. The research suggests that early introductions to adu...
Researchers found that patients with sickle cell disease experience significant distress from anticipating and attending emergency departments to manage acute pain flares. The study also revealed stigma and racism in care settings, leading to a lack of control over pain management plans.
The Indiana Sickle Cell Dashboard presents interactive visualizations of the disease's prevalence and burden across an entire state, offering a comprehensive picture of those living with sickle cell. The dashboard provides rates per 100,000 population, allowing for comparisons between states or areas around the world.
Individuals living with sickle cell disease who experience delays in transitioning to adult care are twice as likely to be hospitalized, according to a study. Patients who transition within six months have more outpatient visits and better health outcomes.
A phase 3 clinical trial found that 96.7% of patients did not experience severe vaso-occlusive crises, and all remained hospitalization-free for at least one year after receiving the gene therapy CASGEVY.